Mutation of P53 in head and neck squamous cell carcinoma correlates with BCL-2 expression and increased susceptibility to cisplatin-induced apoptosis

Background. The p53 protein, a well-known tumor suppressor that functions primarily as a transcription factor, initiates cell cycle arrest and apoptosis after genotoxic stress. The antiapoptotic regulator Bcl-2 is a downstream modulator of p53-induced apoptosis. Loss of function of the p53 tumor suppressor through mutation is an important event that contributes to cellular transformation. Mutation of p53 is one of the most common genetic alterations in squamous cell carcinomas of the head and neck (SCCHN). We hypothesized that p53 mutation is associated with Ecl-2 expression and susceptibility to apoptosis in SCCHN. Methods. Exons 5 to 8 of the p53 gene were sequenced in 22 SCCHN tumor samples and correlated with the 3cl-2 expression and apoptosis rates in these tumors. In addition, a Ecl-2-expressing SCCHN cell line, UMSCC74B, was stably transfected with a temperature-sensitive mutant p53 construct, and 3cl-2 expression levels were examined at the mutant and the wild-type temperatures. Results. Ecl-2 expression was inversely correlated with wildtype p53 status in SCCHN tumors (p =.05). Furthermore, there was a modest increase (1.7-fold) in apoptosis in the wild-type p53 tumors compared with mutant p53 SCCHN. Immunoblotting of UMSCC74B cells stably transfected with the temperature-sensitive mutant p53 construct demonstrated that shifting these cells to the mutant p53 temperature (39.5degreesC) resulted in decreased expression of Ecl-2 compared with levels in cells grown at the wild-type p53 temperature (32.5degreesC). Further investigation showed that SCCHN cells expressing predominantly mutant p53 and decreased Ecl-2 were more susceptible to cisplatin-induced apoptosis than vector-transfected controls (p < .0001). Conclusions. These results suggest that p53 mutation directly modulates Ecl-2 expression and therefore susceptibility to chemotherapy-induced apoptosis in SCCHN cells in vitro. (C) 2004 Wiley Periodicals, Inc.